Karlin Daniel sold $452K of DFTX

Karlin Daniel (Chief Medical Officer) sold 10,035 shares of Definium Therapeutics, Inc. (DFTX) at $45.03 ($0.45M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Karlin Daniel
Published Jun 26, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFTX
Neutral
high confidence
Mentioned
$DFTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXNeutralLow
01

Why it matters

The disclosure provides a fresh datapoint on insider behavior but lacks new operational information, so it is more relevant for sentiment/positioning than for fundamental repricing.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing reduces the signal strength.

03

What to watch

The filing does not disclose any new clinical, regulatory, or financial catalyst; traders should avoid over-weighting insider-sale headlines without corroborating fundamentals.

Relevance 3/10Novelty 5/10Timing: after-hours / same day as the Form 4 filing (2026-06-26)

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the company’s Chief Medical Officer.

Company-level read

Ticker impact

$DFTXNeutralHigh confidence
Context

Definium Therapeutics disclosed CMO Karlin Daniel sold 10,035 shares in an open-market transaction under a 10b5-1 plan on 2026-06-25.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

This is an SEC Form 4 insider transaction with a stated 10b5-1 pre-arranged plan and no accompanying operational or financial update.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • Definium Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Karlin Daniel

    Chief Medical Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFTXHighAI 8/10

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXMedAI 8/10

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT